Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia
A Randomized, Double-blind, Placebo-controlled, Repeated-dosing, Multiple Ascending Dose Trial to Evaluate the Safety and Tolerability of a Novel PCSK-9 Anti-body, IBI306, in Chinese Patients With Hypercholesterolemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Peking University First Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria in order to be included in the study:
- Provide a signed and dated informed consent form;
- Men or women with an age of 18 to 70 years of age at screening (Inclusive);
- BMI between18kg/m2 and 30kg/m2(Inclusive);
- Diagnosis of hyperlipidemia, and taking statins with moderate doses or above for at least 4 weeks;
- Fasting LDL-C between 100 mg / dl (2.6 mmol / L) and 220 mg / dl (5.7 mmol / L) at screening (Inclusive);
- Fasting triglycerides ≤ 400 mg (4.5 mmol / L) at screening.
Exclusion Criteria:
Subjects who do not meet any of the following exclusion criteria cannot be included in the study:
- Subject's current statin treatment are stable less than 4 weeks prior to random enrollment
- New York Heart Association (NYHA) III or IV heart failure, or last left ventricular ejection fraction <30%
- Uncontrolled hypertension, defined as repeated measurements confirmed, sitting systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg.
Diabetic patients have one of the following conditions;
- Known microvascular and macrovascular complications
- HbA1c>7.5% within 4 weeks before screening
- Moderate or severe renal insufficiency, defined as the estimated glomerular filtration rate <60 ml / min / 1.73 m2 during screening (calculated using the MDRD formula)
- Active liver disease or impaired liver function, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the normal upper limit (ULN) at screening.
- Have previously undergone liver transplant surgery.
- Creatine kinase (CK) ≥ 3 times the upper limit of normal (ULN) at screening.
- At the discretion of the investigator, there are known active infections or major blood, kidney, metabolism, gastrointestinal or endocrine dysfunction.
- Female subject of childbearing potential not willing to use an acceptable method(s) of effective birth control during treatment with investigational product and for an additional 15 weeks after the end of treatment with investigational product. Male subjects are reluctant to inform their female sexual partners about their participation in the clinical study.
- Female subject is pregnant or breast feeding, planning to become pregnant or planning to breastfeed during treatment with investigational product and/or within 15 weeks after the end of treatment with investigational product..
- Subjects have been treated with PCSK9 inhibitors or have participated in other PCSK-9 inhibitor studies
- Subject has known sensitivity to the study drug and its excipients
- Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment (for example, alcohol or other substance abuse, unable or unwilling to comply with the agreement or mental illness).
- Currently receiving treatment in another investigational device or drug study, or less than 30 days before randomization since ending treatment on another investigational device or drug study(s) while participating in this study
- In the opinion of the investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: IBI306
Participants received one of 6 dose levels of IBI306 administered as multiple subcutaneous dose
|
Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
|
|
Placebo Comparator: placebo
Participants received matching placebo dose regimen by subcutaneous injection.
|
Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AEs/SAEs
Time Frame: up to 12 weeks
|
• Percentage of participants with adverse events and severity of adverse events from the first dose to the last visit
|
up to 12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cmax
Time Frame: up to 12 weeks
|
up to 12 weeks
|
|
|
Tmax
Time Frame: up to 12 weeks
|
up to 12 weeks
|
|
|
area under curve (AUC)
Time Frame: up to 12 weeks
|
up to 12 weeks
|
|
|
volume of distribution (Vd)
Time Frame: up to 12 weeks
|
up to 12 weeks
|
|
|
half-life (T1/2)
Time Frame: up to 12 weeks
|
up to 12 weeks
|
|
|
clearance (CL)
Time Frame: up to 12 weeks
|
up to 12 weeks
|
|
|
accumulation factor (AR)
Time Frame: up to 12 weeks
|
up to 12 weeks
|
|
|
changes in blood PCSK-9 concentrations at different time points before and after administration relative to baseline
Time Frame: up to 12 weeks
|
up to 12 weeks
|
|
|
ADA
Time Frame: up to 12 weeks
|
The occurrence of anti-IBI306 antibody (ADA) in serum before and after administration
|
up to 12 weeks
|
|
NAb
Time Frame: up to 12 weeks
|
The occurrence of neutralizing antibody (NAb) in serum before and after administration
|
up to 12 weeks
|
|
Percent change in LDL-C from baseline at 12 weeks
Time Frame: baseline and week 12
|
baseline and week 12
|
|
|
Changes in LDL-C levels from baseline at 12 weeks
Time Frame: baseline and week 12
|
baseline and week 12
|
|
|
Percent change in non-HDL-C cholesterol levels from baseline at 12 weeks
Time Frame: baseline and week 12
|
baseline and week 12
|
|
|
Percent change in ApoB from baseline at 12 weeks
Time Frame: baseline and week 12
|
baseline and week 12
|
|
|
Percent change in ApoB/ApoA1 ratio from baseline at 12 weeks
Time Frame: baseline and week 12
|
baseline and week 12
|
|
|
Percent of patients with a 15% or more decrease in LDL-C levels from baseline at 12 weeks
Time Frame: baseline and week 12
|
baseline and week 12
|
|
|
Percent change in Lp(a) from baseline at 12 weeks
Time Frame: baseline and week 12
|
baseline and week 12
|
|
|
Percent change in mean LDL-C levels at week 6 and 12 relative to baseline
Time Frame: baseline, week 6 and 12
|
baseline, week 6 and 12
|
|
|
Percent change in mean ApoB levels at week 6 and 12 relative to baseline
Time Frame: baseline, week 6 and 12
|
baseline, week 6 and 12
|
|
|
Percent change in mean Lp(a) levels at week 6 and 12 relative to baseline
Time Frame: baseline, week 6 and 12
|
baseline, week 6 and 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yiming Cui, Peking University First Hospital
- Principal Investigator: Huo Yong, Peking University First Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CIBI306B101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.